- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
DCT Opportunities in Clinical Research
A discussion of the biggest digital trends in clinical research, how COVID-19 impacted digital use for sponsors/CROs, what the future of DCT services looks like, and more.
Edward Triebell, Commercial Executive Director for MRN Technologies, discusses the biggest digital trends in clinical research right now, how COVID-19 impacted the use of digital within sponsors and CROs, what the future of DCT services looks like, and more.
About the speaker
Edward Triebell is the Executive Director of Digital Health at Medical Research Network (MRN) and leads their strategy on empowering the use of digital technology in MRN’s Decentralized Clinical Trials services.
Mr. Triebell has been on the forefront of disruptive innovations in the development and application of digital technology for companies in the telecommunications, software, and healthcare industries. He started his career in design engineering and then transitioned into project engineering, program management, and sales eventually running global sales and marketing teams for technology focused enterprises, providing a wide lens on the requirements, development and launch of successful digital products and services.
For the past several years, Mr. Triebell has been involved in equity funded strategic roles. His most recent role pivoted an Internet of Things (IoT) software platform into an eCOA solution for successful acquisition by a CRO.
Within the healthcare industry, Mr. Triebell has been involved with programs including a telemedicine network for the Mayo Clinic network of hospitals to accomplish remote diagnosis and surgical treatments with high resolution imaging/videos, RFID solutions for patient tracking within Emergency Departments as well as audited tracking of patient biological samples and outsourcing radiological contouring for cancer treatments using a joint venture with China’s leading Cancer hospital.
Mr. Triebell earned his bachelor’s degree in electrical engineering and completed graduate coursework for his dual master’s degree in electrical engineering/engineering management from Florida Institute of Technology. He also completed an Executive Management program at the Wharton School of Business.
About the Pharm Exec Podcast
The editors of Pharmaceutical Executivebring you the latest commercial insights to master the science of success. Podcast episodes examine current trends, key conferences, and critical topics in the bio/pharmaceutical industry.
Listen to this podcast on SoundCloud, Spotify, Google Podcasts, or Apple Podcasts.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
